Alemtuzumab: Rare serious adverse events of a high-efficacy drug-Reference-Cited by-同舟云学术

Alemtuzumab: Rare serious adverse events of a high-efficacy drug

Published:2020-04-16 Issue:6 Volume:26 Page:737-740
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Hartung Hans-Peter¹,Mares Jan²,Barnett Michael H³

Affiliation:

1. Department of Neurology, UKD and Center for Neurology and Neuropsychiatry, LVR Klinikum, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

2. Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic

3. Department of Neurology, Royal Prince Alfred Hospital and Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458520913277

Reference13 articles.

1. Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis

2. Alemtuzumab CARE-MS II 5-year follow-up

3. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis

4. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

5. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autoimmune Skin Diseases in Multiple Sclerosis: Comorbidity Issues and the Impact of Pathogenetic Therapy;Annals of the Russian academy of medical sciences;2024-02-29

2. Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen;Multiple Sclerosis and Related Disorders;2022-10

3. Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management;Neurotherapeutics;2022-04

4. Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection;Clinical Pharmacology & Therapeutics;2022-03-08

5. Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis;Therapeutic Advances in Neurological Disorders;2022-01